Category: Hem/Onc News
HEM/ONC News
Clinical Advances in Hematology & Oncology April 2014, Volume 12, Issue 4 By Devon Schuyler Termination Recommended for Phase 3 Trial of Onartuzumab in NSCLC An independent […]
Hem/Onc News
Clinical Advances in Hematology & Oncology March 2014, Volume 12, Issue 3 By Devon Schuyler FDA Approves Ibrutinib for Use in Chronic Lymphocytic Leukemia The US Food […]
Hem/Onc News
Clinical Advances in Hematology & Oncology February 2014, Volume 12, Issue 2 HEM/ONC News By Devon Schuyler Anastrozole Reduces Breast Cancer in Postmenopausal Women at High […]
Ibrutinib Approved for the Treatment of Mantle Cell Lymphoma
Clinical Advances in Hematology & Oncology December 2013, Volume 11, Issue 12 HEM/ONC News By Stacey Small Ibrutinib Approved for the Treatment of Mantle Cell Lymphoma On […]
A Summer of Change in Hematologic Malignancies: Highlights in B-Cell Malignancies From the 2013 ASCO, EHA, and ICML Meetings
Clinical Advances in Hematology & Oncology November 2013, Volume 11, Issue 11 A Summer of Change in Hematologic Malignancies: Highlights in B-Cell Malignancies From the 2013 ASCO, EHA, and […]
October News
Clinical Advances in Hematology & Oncology October 2013, Volume 11, Issue 10 FDA Panel Supports Accelerated Approval of Pertuzumab for Neoadjuvant Treatment in HER2-Positive, Early-Stage Breast Cancer […]
Hem/Onc News
Clinical Advances in Hematology & Oncology August 2013, Volume 11, Issue 8 Improved Quality of Life With Eribulin Versus Capecitabine in Metastatic Breast Cancer Patients […]
Hem/Onc News
Clinical Advances in Hematology & Oncology July 2013, Volume 11, Issue 7 Bevacizumab Significantly Improves Survival in Patients With Recurrent Cervical Cancer According to a […]
Hem/Onc News
Clinical Advances in Hematology & Oncology May 2013, Volume 11, Issue 5 Trastuzumab in HER2-Positive Lobular Breast Cancer: Results From the HERA Trial In an […]
Hem/Onc News
Clinical Advances in Hematology & Oncology April 2013, Volume 11, Issue 4 Regorafenib Approved in GIST In February 2013, the US Food and Drug Administration (FDA) […]
Hem/Onc News
Clinical Advances in Hematology & Oncology February 2013, Volume 11, Issue 2 Long-Term Overall Survival Improved With the Addition of Trastuzumab to Chemotherapy in Patients […]
December News
Clinical Advances in Hematology & Oncology December 2012, Volume 10, Issue 12 Hem/Onc News Bevacizumab Improves PFS in Glioblastoma: Results From the Phase III AVAglio Study […]
August News
Accelerated Approval of Carfilzomib for Patients With Refractory Multiple Myeloma On July 20, 2012, the US Food and Drug Administration (FDA) granted accelerated approval of carfilzomib […]
Highlights From the 2012 American Society of Clinical Oncology (ASCO) Meeting
Chemotherapy Plus Radiation Extends Survival in Patients With Anaplastic Oligodendroglial Tumors: Long-Term Follow-Up Results of EORTC 26951 Van Den Bent and associates presented long-term follow-up results […]
May News
Addition of Chemotherapy to Radiotherapy Reduces Locoregional Recurrence of Muscle-Invasive Bladder Cancer Results from a multicenter, randomized study by James and associates demonstrated that patients with […]
April News
Pemetrexed Maintenance Therapy Following Induction Therapy in Advanced NSCLC According to a study in the February 16 online issue of The Lancet Oncology by Paz-Ares and associates, […]
Highlights From the 2011 San Antonio Breast Cancer Symposium
December 6–10, 2011 • San Antonio, Texas Complete abstracts are available at http://www.sabcs.org P5-19-03 Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer […]
January News
Hem/Onc News Long-Term Data Suggest Chemotherapy Alone Is Superior to Radiation-Based Therapy in Patients With Limited-Stage Hodgkin Lymphoma According to research published in the December 11 […]
December News
Rindopepimut for Newly Diagnosed EGFRvIII-Positive Glioblastoma: Mature Survival Data from the ACTIII Trial Mature overall survival (OS) data from ACT III, a multi-center, single arm, phase […]
November News
Castration-Resistant Prostate Cancer Patients Achieve Delayed Bone Metastases With Denosumab Subanalyses of the phase III denosumab 147 study were presented on September 25 at the European […]